相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelody-splastic syndromes and acute myeloid leukemia
Nabih Maslah et al.
HAEMATOLOGICA (2020)
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
C. D. DiNardo et al.
BLOOD (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
Guillermo Montalban-Bravo et al.
BLOOD ADVANCES (2020)
TP53 and therapy-related myeloid neoplasms
Jae Chung et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Detlef Haase et al.
LEUKEMIA (2019)
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
Nicholas J. Short et al.
LANCET HAEMATOLOGY (2019)
Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations
Stefan O. Ciurea et al.
BLOOD (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Income and Cancer Overdiagnosis - When Too Much Care Is Harmful
H. Gilbert Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
D. A. Sallman et al.
LEUKEMIA (2016)
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
Cecile Bally et al.
LEUKEMIA RESEARCH (2014)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
Austin G. Kulasekararaj et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Soren Lehmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)